Cancer diagnoses traditionally require invasive or labor-intensive procedures such as tissue biopsies. Researchers at the Ludwig-Maximilians-Universität München (LMU) have now reported on a method ...

PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting ...

Findings support model in which accelerated biological aging of mammary epithelia may underpin breast cancer susceptibility ...

An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...

A new liquid biopsy test using artificial intelligence models could help spot a rare type of bone and soft tissue cancer that ...

TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...

Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...

The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023.  The ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.